Slide 1

268 / 1631

UK RAPID; EORTC/LYSA H10
RT or no RT in PET-negative early stage HL
• Central PET review necessary
• More events in PET- patients with chemo only
• Similar findings but opposite conclusions (8 vs 20 and 8 vs 25
events) between RAPID1 and H10 2
• Rapid failed to demonstrate non-inferiority (HR 1.57; p=0.27) with
PFS differences of up to 8.8% (ITT) and 11.0% (per protocol)
• No difference between PET+ and PET- patients – questionable role
of PET in this setting!
• Deleting RT in PET- early stage HL still experimental
1Radford et al; NEJM 2015
2Raemakers et al; JCO 2015